While the outcome measures in these different trials have varied (from weight reduction to hepatic steatosis reduction to liver enzyme changes), the use of GLP-1 RAs to treat the spectra of non-alcoholic fatty liver diseases has shown some encouraging and interesting results. This evidence concerns the gene GLP1R and Hepatic steatosis.